108 related articles for article (PubMed ID: 1567873)
1. Synthesis and conformational studies of N-glycosylated analogues of the HIV-1 principal neutralizing determinant.
Laczkó I; Hollósi M; Urge L; Ugen KE; Weiner DB; Mantsch HH; Thurin J; Otvös L
Biochemistry; 1992 May; 31(17):4282-8. PubMed ID: 1567873
[TBL] [Abstract][Full Text] [Related]
2. Solution conformational preferences of immunogenic peptides derived from the principal neutralizing determinant of the HIV-1 envelope glycoprotein gp120.
Chandrasekhar K; Profy AT; Dyson HJ
Biochemistry; 1991 Sep; 30(38):9187-94. PubMed ID: 1892828
[TBL] [Abstract][Full Text] [Related]
3. Secondary structural elements as a basis for antibody recognition in the immunodominant region of human immunodeficiency viruses 1 and 2.
Markert RL; Ruppach H; Gehring S; Dietrich U; Mierke DF; Köck M; Rübsamen-Waigmann H; Griesinger C
Eur J Biochem; 1996 Apr; 237(1):188-204. PubMed ID: 8620873
[TBL] [Abstract][Full Text] [Related]
4. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of an N-glucoasparagine analog as a building block for a V3-loop glycopeptide from gp120 of HIV-I.
Schäfer A; Klich G; Schreiber M; Paulsen H; Thiem J
Carbohydr Res; 1998 Dec; 313(2):107-16. PubMed ID: 9880906
[TBL] [Abstract][Full Text] [Related]
6. Structural comparison of a 15 residue peptide from the V3 loop of HIV-1IIIb and an O-glycosylated analogue.
Huang X; Smith MC; Berzofsky JA; Barchi JJ
FEBS Lett; 1996 Sep; 393(2-3):280-6. PubMed ID: 8814305
[TBL] [Abstract][Full Text] [Related]
7. Solution conformation of a peptide corresponding to the principal neutralizing determinant of HIV-1IIIB: a two-dimensional NMR study.
Zvi A; Hiller R; Anglister J
Biochemistry; 1992 Aug; 31(30):6972-9. PubMed ID: 1637831
[TBL] [Abstract][Full Text] [Related]
8. Glycosylation affects both the three-dimensional structure and antibody binding properties of the HIV-1IIIB GP120 peptide RP135.
Huang X; Barchi JJ; Lung FD; Roller PP; Nara PL; Muschik J; Garrity RR
Biochemistry; 1997 Sep; 36(36):10846-56. PubMed ID: 9312273
[TBL] [Abstract][Full Text] [Related]
9. Correlation of antiviral activity with beta-turn types for V3 synthetic multibranched peptides from HIV-1 gp120.
Mabrouk K; Van Rietschoten J; Rochat H; Loret EP
Biochemistry; 1995 Jul; 34(26):8294-8. PubMed ID: 7599121
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and conformational analysis of N-glycopeptides. II. CD, molecular dynamics, and NMR spectroscopic studies on linear N-glycopeptides.
Perczel A; Kollát E; Hollósi M; Fasman GD
Biopolymers; 1993 Apr; 33(4):665-85. PubMed ID: 8467070
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of glycosylated tuftsins and tuftsin-containing IgG fragment undecapeptide.
Biondi L; Filira F; Gobbo M; Scolaro B; Rocchi R
Int J Pept Protein Res; 1991 Feb; 37(2):112-21. PubMed ID: 2019473
[TBL] [Abstract][Full Text] [Related]
12. Conformation of the principal neutralizing determinant of human immunodeficiency virus type 1 in complex with an anti-gp120 virus neutralizing antibody studied by two-dimensional nuclear magnetic resonance difference spectroscopy.
Zvi A; Feigelson DJ; Hayek Y; Anglister J
Biochemistry; 1997 Jul; 36(28):8619-27. PubMed ID: 9214308
[TBL] [Abstract][Full Text] [Related]
13. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1.
Javaherian K; Langlois AJ; LaRosa GJ; Profy AT; Bolognesi DP; Herlihy WC; Putney SD; Matthews TJ
Science; 1990 Dec; 250(4987):1590-3. PubMed ID: 1703322
[TBL] [Abstract][Full Text] [Related]
14. Stabilization of the biologically active conformation of the principal neutralizing determinant of HIV-1(IIIB) containing a cis-proline surrogate: 1H NMR and molecular modeling study.
Garcia J; Dumy P; Rosen O; Anglister J
Biochemistry; 2006 Apr; 45(13):4284-94. PubMed ID: 16566603
[TBL] [Abstract][Full Text] [Related]
15. Peptides mimicking selected disulfide loops in HIV-1 gp120, other than V3, do not elicit virus-neutralizing antibodies.
Neurath AR; Strick N; Fields R; Jiang S
AIDS Res Hum Retroviruses; 1991 Aug; 7(8):657-62. PubMed ID: 1718344
[TBL] [Abstract][Full Text] [Related]
16. Recognition properties of V3-specific antibodies to V3 loop peptides derived from HIV-1 gp120 presented in multiple conformations.
Huisman JG; Carotenuto A; Labrijn AF; Papavoine CH; Laman JD; Schellekens MM; Koppelman MH; Hilbers CW
Biochemistry; 2000 Sep; 39(35):10866-76. PubMed ID: 10978173
[TBL] [Abstract][Full Text] [Related]
17. Antigenicity and predefined specificities of the multi-epitope vaccine in candidate consisting of neutralizing epitope and mutated epitopes suggested a new way against HIV-1 mutation.
Tian H; Xiao Y; Qin L; Chen YH
Immunobiology; 2001 Dec; 204(4):434-41. PubMed ID: 11776398
[TBL] [Abstract][Full Text] [Related]
18. The effects of post-translational side-chain modifications on the stimulatory activity, serum stability and conformation of synthetic peptides carrying T helper cell epitopes.
Otvos L; Cappelletto B; Varga I; Wade JD; Xiang ZQ; Kaiser K; Stephens LJ; Ertl HC
Biochim Biophys Acta; 1996 Aug; 1313(1):11-9. PubMed ID: 8781544
[TBL] [Abstract][Full Text] [Related]
19. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
[TBL] [Abstract][Full Text] [Related]
20. Antibody responses of chimpanzees immunized with synthetic peptides corresponding to full-length V3 hypervariable loops of HIV-1 envelope glycoproteins.
Neurath AR; Jiang S; Strick N; Kolbe H; Kieny MP; Muchmore E; Girard M
AIDS Res Hum Retroviruses; 1991 Oct; 7(10):813-23. PubMed ID: 1720628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
